{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:41:36Z","timestamp":1767109296316,"version":"3.40.5"},"reference-count":44,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Ministry of Research and the Ministry of Health of Tunisia"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Immunology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.humimm.2015.03.011","type":"journal-article","created":{"date-parts":[[2015,4,6]],"date-time":"2015-04-06T01:44:17Z","timestamp":1428284657000},"page":"301-306","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Interleukin-33 and Beh\u00e7et disease: Another cytokine among others"],"prefix":"10.1016","volume":"76","author":[{"given":"Kamel","family":"Hamzaoui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4829-3098","authenticated-orcid":false,"given":"Eya","family":"Bouali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Hamzaoui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.humimm.2015.03.011_b0005","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.4049\/jimmunol.1202677","article-title":"Role of IL-22- and TNF-\u03b1-producing Th22 cells in uveitis patients with Behcet\u2019s disease","volume":"190","author":"Sugita","year":"2013","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.humimm.2015.03.011_b0010","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2249.2011.04543.x","article-title":"Excessive CD4+ T cells co-expressing interleukin-17 and interferon-\u03b3 in patients with Beh\u00e7et\u2019s disease","volume":"168","author":"Shimizu","year":"2012","journal-title":"Clin. Exp. Immunol."},{"issue":"4 Suppl 67","key":"10.1016\/j.humimm.2015.03.011_b0015","first-page":"S71","article-title":"Th17 cells in Beh\u00e7et\u2019s disease: a new immunoregulatory axis","volume":"29","author":"Hamzaoui","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"1\u20132","key":"10.1016\/j.humimm.2015.03.011_b0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jneuroim.2011.01.012","article-title":"RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Beh\u00e7et\u2019s disease","volume":"233","author":"Hamzaoui","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.humimm.2015.03.011_b0025","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/eop.12.30","article-title":"Immunological responses in patients with Beh\u00e7et\u2019s disease: advances in understanding","volume":"7","author":"Hamzaoui","year":"2012","journal-title":"Expert Rev. Ophthalmol."},{"issue":"10","key":"10.1016\/j.humimm.2015.03.011_b0030","first-page":"1428","article-title":"Production of TNF-alpha and IL-1 in active Beh\u00e7et\u2019s disease","volume":"17","author":"Hamzaoui","year":"1990","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.humimm.2015.03.011_b0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/030097402320318387","article-title":"Cytokine profile in Beh\u00e7et\u2019s disease patients. relationship with disease activity","volume":"31","author":"Hamzaoui","year":"2002","journal-title":"Scand. J. Rheumatol."},{"issue":"5","key":"10.1016\/j.humimm.2015.03.011_b0040","doi-asserted-by":"crossref","first-page":"962","DOI":"10.3899\/jrheum.101202","article-title":"IL18 polymorphism is associated with Beh\u00e7et\u2019s disease but not lupus in patients from Turkey","volume":"38","author":"Htoon","year":"2011","journal-title":"J. Rheumatol."},{"issue":"6","key":"10.1016\/j.humimm.2015.03.011_b0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00296-005-0029-8","article-title":"Serum interleukin-18 levels in patients with Beh\u00e7et\u2019s disease. Is its expression associated with disease activity or clinical presentations?","volume":"26","author":"Musabak","year":"2006","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.humimm.2015.03.011_b0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2249.2007.03441.x","article-title":"The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders","volume":"149","author":"Barksby","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.humimm.2015.03.011_b0055","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/14397595.2013.844304","article-title":"Interleukin-1-related genes polymorphisms in Beh\u00e7et disease: a meta-analysis","volume":"24","author":"Zou","year":"2014","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.humimm.2015.03.011_b0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.humimm.2015.03.011_b0065","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1073\/pnas.0606854104","article-title":"IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo","volume":"104","author":"Carriere","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.humimm.2015.03.011_b0070","doi-asserted-by":"crossref","first-page":"18581","DOI":"10.1073\/pnas.1003059107","article-title":"IL-33 is a crucial amplifier of innate rather than acquired immunity","volume":"107","author":"Oboki","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.humimm.2015.03.011_b0075","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.4049\/jimmunol.179.4.2551","article-title":"IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex","volume":"179","author":"Chackerian","year":"2007","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0080","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cyto.2008.03.008","article-title":"The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33","volume":"42","author":"Palmer","year":"2008","journal-title":"Cytokine"},{"key":"10.1016\/j.humimm.2015.03.011_b0085","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.M704916200","article-title":"Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation","volume":"282","author":"Hayakawa","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"8","key":"10.1016\/j.humimm.2015.03.011_b0090","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.4049\/jimmunol.1400481","article-title":"IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R\/ST2+ regulatory T cells","volume":"193","author":"Matta","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0095","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.4049\/jimmunol.0802729","article-title":"The essential role of single Ig IL-1 receptor-related molecule\/Toll IL-1R8 in regulation of Th2 immune response","volume":"182","author":"Bulek","year":"2009","journal-title":"J. Immunol."},{"issue":"17","key":"10.1016\/j.humimm.2015.03.011_b0100","doi-asserted-by":"crossref","first-page":"11829","DOI":"10.1074\/jbc.M113.534396","article-title":"IFN-\u03b3 directly controls IL-33 protein level through a STAT1- and LMP2-dependent mechanism","volume":"289","author":"Kopach","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.humimm.2015.03.011_b0105","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.3899\/jrheum.100184","article-title":"Elevated serum interleukin 33 is associated with autoantibody production in patients with rheumatoid arthritis","volume":"37","author":"Mu","year":"2010","journal-title":"J. Rheumatol."},{"issue":"9","key":"10.1016\/j.humimm.2015.03.011_b0110","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.humimm.2013.06.029","article-title":"IL-33 in rheumatoid arthritis: potential role in pathogenesis and therapy","volume":"74","author":"Xu","year":"2013","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0115","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10238-010-0115-4","article-title":"Association of increased serum IL-33 levels with clinical and laboratory characteristics of systemic lupus erythematosus in Chinese population","volume":"11","author":"Yang","year":"2011","journal-title":"Clin. Exp. Med."},{"issue":"8","key":"10.1016\/j.humimm.2015.03.011_b0120","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3346\/jkms.2013.28.8.1145","article-title":"Serum level of interleukin-33 and soluble ST2 and their association with disease activity in patients with Behcet\u2019s disease","volume":"28","author":"Kim","year":"2013","journal-title":"J. Korean Med. Sci."},{"issue":"3 Suppl 77","key":"10.1016\/j.humimm.2015.03.011_b0125","first-page":"6","article-title":"Serum IL-33 levels and skin mRNA expression in Beh\u00e7et\u2019s disease","volume":"31","author":"Hamzaoui","year":"2013","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.humimm.2015.03.011_b0130","article-title":"Serum IL-33 level and IL-33 gene polymorphisms in Beh\u00e7et\u2019s disease","author":"Koca","year":"2014","journal-title":"Rheumatol. Int."},{"issue":"11","key":"10.1016\/j.humimm.2015.03.011_b0135","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1002\/eji.201444671","article-title":"IL-33 attenuates the development of experimental autoimmune uveitis","volume":"44","author":"Barbour","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0140","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/art.21145","article-title":"NF-kappaB protects Beh\u00e7et\u2019s disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins","volume":"52","author":"Todaro","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.humimm.2015.03.011_b0145","doi-asserted-by":"crossref","first-page":"e18404","DOI":"10.1371\/journal.pone.0018404","article-title":"Paracrine IL-33 stimulation enhances lipopolysaccharide-mediated macrophage activation","volume":"6","author":"Ohno","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.humimm.2015.03.011_b0150","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.4049\/jimmunol.177.9.6415","article-title":"Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers","volume":"177","author":"Melikoglu","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0155","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1073\/pnas.0901206106","article-title":"The cytokine interleukin-33 mediates anaphylactic shock","volume":"106","author":"Pushparaj","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.humimm.2015.03.011_b0160","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1002\/eji.201041360","article-title":"IL-33 induces skin inflammation with mast cell and neutrophil activation","volume":"41","author":"Hueber","year":"2011","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0165","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s10067-011-1686-5","article-title":"Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis","volume":"30","author":"Yanaba","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.humimm.2015.03.011_b0170","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.2353\/ajpath.2010.100378","article-title":"Inflammatory bowel disease-associated interleukin-33 is preferentially expressed in ulceration-associated myofibroblasts","volume":"177","author":"Sponheim","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.humimm.2015.03.011_b0175","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1073\/pnas.0712116105","article-title":"IL-33 mediates antigen-induced cutaneous and articular hypernociception in mice","volume":"105","author":"Verri","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.humimm.2015.03.011_b0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jneuroim.2003.08.040","article-title":"Cytokines and chemokines in neuro-Beh\u00e7et\u2019s disease compared to multiple sclerosis and other neurological diseases","volume":"145","author":"Saruhan-Direskeneli","year":"2003","journal-title":"J. Neuroimmunol."},{"issue":"6","key":"10.1016\/j.humimm.2015.03.011_b0185","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/cmi.2014.31","article-title":"Increased interleukin 33 in patients with neuro-Behcet\u2019s disease: correlation with MCP-1 and IP-10 chemokines","volume":"11","author":"Hamzaoui","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1189\/jlb.1207830","article-title":"Induction of IL-33 expression and activity in central nervous system glia","volume":"84","author":"Hudson","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.humimm.2015.03.011_b0195","doi-asserted-by":"crossref","first-page":"L3","DOI":"10.1152\/ajplung.00405.2003","article-title":"Chemokines in acute respiratory distress syndrome","volume":"288","author":"Puneet","year":"2005","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"4","key":"10.1016\/j.humimm.2015.03.011_b0200","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.4049\/jimmunol.1003080","article-title":"The dual function cytokine IL-33 interacts with the transcription factor NF-\u03baB to dampen NF-\u03baB-stimulated gene transcription","volume":"187","author":"Ali","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0205","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jneuroim.2012.03.016","article-title":"IL-33 blockade suppresses the development of experimental autoimmune encephalomyelitis in C57BL\/6 mice","volume":"247","author":"Li","year":"2012","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.brainres.2011.02.045","article-title":"Production and functions of IL-33 in the central nervous system","volume":"1385","author":"Yasuoka","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.humimm.2015.03.011_b0215","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.clim.2011.11.007","article-title":"Interleukin-33 upregulation in peripheral leukocytes and CNS of multiple sclerosis patients","volume":"142","author":"Christophi","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.humimm.2015.03.011_b0220","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbi.2014.08.002","article-title":"Interleukin-33 treatment reduces secondary injury and improves functional recovery after contusion spinal cord injury","volume":"44","author":"Pomeshchik","year":"2015","journal-title":"Brain Behav. Immun."}],"container-title":["Human Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885915001032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0198885915001032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T17:27:22Z","timestamp":1537723642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0198885915001032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0198885915001032"],"URL":"https:\/\/doi.org\/10.1016\/j.humimm.2015.03.011","relation":{},"ISSN":["0198-8859"],"issn-type":[{"type":"print","value":"0198-8859"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-33 and Beh\u00e7et disease: Another cytokine among others","name":"articletitle","label":"Article Title"},{"value":"Human Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humimm.2015.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}